Q301 - ClonoSEQ Measurable Residual Disease (MRD) Testing Services
Contract Opportunity Analysis
The Department of Veterans Affairs, Network Contracting Office 10, is seeking to award a sole-source contract for ClonoSEQ Measurable Residual Disease (MRD) testing services to Adaptive Biotechnologies Corporation. The requirement is for molecular MRD testing services utilizing the proprietary clonoSEQ Assay, which is exclusively provided by Adaptive Biotechnologies, making them the only responsible source capable of fulfilling this need. This testing is crucial for the VA Northeast Ohio Healthcare System's Pathology and Laboratory Medicine Service, as it supports the monitoring of residual disease in patients. Interested parties may submit capability statements to Thomas Bellamy at Thomas.Bellamy@va.gov by 3:00 p.m. EST on November 12, 2025, although this notice is not a request for competitive proposals.